Clinical trials: Suspected Prostate Cancer
Oncology, Prostate Cancer
A Study of [18]F-PSMA-1007 in Patients With Known or Suspected Metastatic Prostate Cancer
A [18]F-PSMA-1007 PET/CT or PET/MRI scan are nuclear medicine tests used to create pictures of the whole body that may show where cells that express Prostate-Specific Membrane Antigen (PSMA) are found.
- Trial name
- NCT05712174
- Testing
- [18]F-PSMA-1007
- Where
- Canada
- Volunteers
- 176 people
- Sponsor
- AHS Cancer Control Alberta
Prostate Cancer
68Ga PSMA 11 PET/MRI and 68Ga RM2 PET/MRI for Biopsy Guidance in Patients With Suspected Prostate Cancer
The objective of the study is to evaluate 68Ga PSMA 11 PET/MRI and 68Ga RM2 PET/MRI for biopsy guidance in patients with suspected prostate cancer.
- Trial name
- NCT03809078
- Testing
- 68Ga RM2, 68Ga-PSMA-11, Investigational PET scanner coils and software
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Andrei Iagaru
Prostate Cancer, Prostate Biopsy
Developing a Safer and More Accurate Device for Biopsies of Suspected Prostate Cancer
To evaluate the use of the CAMbridge PROstate Biopsy devicE (CAMPROBE) as a method of undertaking prostate biopsy as part of their clinical management.
- Trial name
- CAMPROBE (NCT02375035)
- Testing
- CAMPROBE
- Where
- United Kingdom
- Volunteers
- 50 people
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
Prostate Cancer, Prostate Neoplasm
Diagnostic Performance of 18F-PSMA-1007 PET/CT in Suspected Prostate Cancer Patient
The diagnostic tools for detecting patients with early prostate cancer are limited due to poor diagnostic performance. The positron emission tomography (PET) combination with the diagnostic radiopharmacy is a non-invasive tool to…
- Trial name
- NCT05422105
- Testing
- 18F-PSMA-1007
- Where
- 2 sites in Taiwan
- Volunteers
- 230 people
- Sponsor
- Primo Biotechnology Co., Ltd
Prostate Cancer
Conducting Active Surveillance Without Prostate Biopsy for Patients With Low-risk Suspected Prostate Cancer
The goal of this observational study is to evaluate the role of the USTC diagnostic model in risk-adaptive strategies for biopsy decision-making in patients with low-risk suspected prostate cancer in order to reduce unnecessary…
- Trial name
- ASWBP (NCT05940415)
- Testing
- active surveillance
- Where
- China
- Volunteers
- 220 people
- Sponsor
- Anhui Provincial Hospital
Prostate Cancer, Prostate Adenocarcinoma
Copper Cu 64 PSMA I&T PET Imaging in Men With Suspected Recurrence of Prostate Cancer
This is a prospective, open-label Phase 3 study to evaluate copper Cu 64 PSMA I\&T injection for PET/CT imaging in patients with recurrent prostate cancer after radical prostatectomy or radiation therapy.
- Conditions
- Prostate Cancer, Prostate Adenocarcinoma, Biochemical Recurrence of Malignant Neoplasm of Prostate
- Trial name
- Solar-Recur (NCT06235099)
- Testing
- Copper Cu 64 PSMA I&T
- Where
- 31 sites in United States
- Volunteers
- 235 people
- Sponsor
- Curium US LLC
Patients With Suspected Prostate Cancer
Analysis of a New Biomarker for Prostate Cancer Diagnosis
The aim of our study is to determine if the levels of the "HEM" substance in seminal plasma are associated with the presence of prostate cancer in transrectal prostate biopsy.
- Trial name
- HEM (NCT01819740)
- Testing
- determine the levels of the "HEM" substance in seminal plasma
- Where
- Spain
- Volunteers
- 28 people
- Sponsor
- Corporacion Parc Tauli
Health Status Unknown, Prostate Carcinoma
Transrectal MRI-Guided Biopsy in Identifying Cancer in Patients With Suspected Prostate Cancer
This pilot clinical trial studies transrectal magnetic resonance imaging (MRI)-guided biopsy to see how well it works in identifying cancer in patients with suspected prostate cancer who are scheduled to undergo standard biopsy.
- Trial name
- NCT02501759
- Testing
- 3 Tesla Magnetic Resonance Imaging, Gadodiamide, Multiparametric Magnetic Resonance Imaging
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- OHSU Knight Cancer Institute
Prostate Cancer, Prostate Adenocarcinoma
Study of 18F-DCFPyL PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer
This study evaluates the diagnostic performance and safety of 18F-DCFPyL (PyL) PET/CT imaging in patients with suspected recurrence of prostate cancer who have negative or equivocal findings on conventional imaging.
- Conditions
- Prostate Cancer, Prostate Adenocarcinoma, Prostate Cancer Recurrent, Prostate Cancer Metastatic
- Trial name
- CONDOR (NCT03739684)
- Testing
- 18F-DCFPyL, PET/CT Imaging
- Where
- 14 sites in United States, Canada
- Volunteers
- 208 people
- Sponsor
- Progenics Pharmaceuticals, Inc.
Prostate Cancer (Adenocarcinoma)
Assessment of ADC Values and Radiomics Characteristics With a MRI of the Prostate to Identify Tumor Lesions
The goal of this observational study is to assess the chance to predict prostate cancer with the analysis of specific values found in images obtained from RMmp (multiparametric magnetic resonance imaging) of patients who went…
- Trial name
- NCT06774781
- Where
- Italy
- Volunteers
- 120 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Suspected Prostate Cancer
MRI Guided Prostate Biopsy
This study aims to assess the feasibility of magnetic resonance (MR) guided prostate biopsy using a needle holder frame. This frame is used to help position the needle used for the biopsy.
- Trial name
- NCT06302595
- Testing
- MRI-guided prostate biopsy using the needle holder frame.
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Brigham and Women's Hospital
Prostate Cancer
SonoVue Guided Prostate Biopsy
This is a phase III European multicenter, open label, prospective study to assess the diagnostic accuracy of the use of SonoVue contrast agent to guide prostate biopsies in comparison with the current practice of ultrasound…
- Trial name
- NCT00911027
- Testing
- Contrast-enhanced ultrasound guided biopsy, ultrasound guided systematic biopsy
- Where
- 17 sites in Austria, Belgium and 5 more
- Volunteers
- 282 people
- Sponsor
- Bracco Diagnostics, Inc
Prostate Cancer
PET/MRI in Patients With Suspected Prostate Cancer
This diagnostic clinical trial will be conducted according to a randomized, prospective, controlled, double-arm, single-centre design.
- Trial name
- NCT02659527
- Testing
- 68Ga- PSMA-HBED-CC, Biograph mMR, Siemens
- Where
- Austria
- Volunteers
- 220 people
- Sponsor
- Medical University of Vienna
Suspected Prostate Cancer (increased PSA Level)
Oncological Prognosis of Prostate Lesions by Chemical Exchange Saturation Transfer Magnetic Resonance Imaging (CEST-MRI)
Prostate cancer is the second most common type of cancer in men only after lung cancer, and accounts for ~3.8% of all deaths caused in men in 2018.
- Trial name
- ProstaCEST (NCT06669273)
- Testing
- CEST MRI sequence at 3T
- Where
- France
- Volunteers
- 70 people
- Sponsor
- University Hospital, Clermont-Ferrand
Prostate Cancer
This Study Evaluates the Diagnostic Performance and Safety of 68Ga-NYM032 PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer.
This study evaluates the diagnostic performance and safety of 68Ga-NYM032 PET/CT imaging in patients with suspected recurrence of prostate cancer.
- Trial name
- NCT07649122
- Testing
- 68-Ga-NYM032
- Where
- 2 sites in China
- Volunteers
- 232 people
- Sponsor
- Norroy Bioscience Co., LTD
Prostate Cancer
Study of 18F-Florastamin PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer
In this study, 18F-Florastamin PET/CT will be performed in patients with suspected recurrence of prostate cancer, to assess the diagnostic performance and safety of 18F-Florastamin PET/CT imaging.
- Trial name
- NCT06754085
- Testing
- Florastamin[18F] Injection
- Where
- China
- Volunteers
- 131 people
- Sponsor
- HTA Co., Ltd.
Metastatic Malignant Neoplasm in Lymph Node, Prostate Ductal Adenocarcinoma
Antiandrogen Therapy With or Without Axitinib Before Surgery in Treating Patients With Previously Untreated Prostate Cancer With Known or Suspected Lymph Node Metastasis
This randomized phase IIA trial studies how well antiandrogen therapy works with or without axitinib before surgery in treating patients with previously untreated prostate cancer that is known or suspected to have spread to lymph…
- Conditions
- Metastatic Malignant Neoplasm in Lymph Node, Prostate Ductal Adenocarcinoma, Stage III Prostate Adenocarcinoma AJCC v7, Stage IV Prostate Adenocarcinoma AJCC v7
- Trial name
- NCT01409200
- Testing
- Antiandrogen Therapy, Axitinib, Radical Prostatectomy
- Where
- United States
- Volunteers
- 73 people
- Sponsor
- M.D. Anderson Cancer Center
Prostate Cancer
3-Tesla MRI in Finding Tumors in Patients With Known or Suspected Prostate Cancer
In standard clinical care, the prostate is imaged by magnetic resonance imaging (MRI) which is a procedure to take pictures of body structures by using a strong magnetic field and radio waves.
- Trial name
- NCT01653093
- Testing
- 3-Tesla magnetic resonance imaging (3T MRI), diffusion-weighted magnetic resonance imaging, dynamic contrast-enhanced magnetic resonance imaging
- Where
- United States
- Volunteers
- 280 people
- Sponsor
- University of Cincinnati
Prostate Cancer
Imaging Study to Investigate Safety and Diagnostic Performance of 18F rhPSMA 7.3 PET Ligand in Suspected Prostate Cancer Recurrence
A prospective, Phase 3, multi center, single-arm, imaging study investigating the safety and diagnostic performance of rhPSMA 7.3 (18F) Positron Emission Tomography (PET) ligand in men with suspected prostate cancer recurrence…
- Trial name
- NCT04186845
- Testing
- rhPSMA-7.3 (18F) Injection, Positron emission tomography scan
- Where
- 28 sites in United States, Finland and 1 more
- Volunteers
- 391 people
- Sponsor
- Blue Earth Diagnostics
Prostate Cancer Recurrent
A Multicenter, Open-label, Prospective Phase III Clinical Trial to Evaluate INR101 Injection for PET/CT Imaging in Participants With Suspected Recurrent Prostate Cancer After Radical Treatment
A multicenter, open-label, prospective Phase III clinical trial to evaluate INR101 injection for PET/CT imaging in participants with suspected recurrent prostate cancer after radical treatment.
- Trial name
- NCT06922929
- Testing
- INR101
- Where
- 32 sites in China
- Volunteers
- 110 people
- Sponsor
- Yunhe Pharmaceutical (Tianjin) Co., Ltd